BridgeBio Pharma initiated with Overweight rating, $80 price target by Barclays.

miércoles, 28 de enero de 2026, 8:33 am ET1 min de lectura
BBIO--

BridgeBio Pharma initiated with Overweight rating, $80 price target by Barclays.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios